Coxiella burnetii (Q-Fever) Phase 1 IgG ELISA

Enzyme immunoassay for the determination of IgG-class antibodies against Coxiella burnetii in human serum

For research use only, not for use in diagnostic procedures.
1. INTRODUCTION

Q-Fever is a disease that results from infection with small, polymorph and gram-negative bacteria called Coxiella burnetii. After an outbreak in Brisbane, Australia, the responsible organism was isolated and named Coxiella burnetii in honour of Dr. Herald Rae Cox and Sir Frank Burnet. New molecular research demonstrated a close relationship to Legionella. The zoonosis Q-Fever is found everywhere except New Zealand (no data available). There is an extensive reservoir (mainly ticks) of C. burnetii. Ticks are an important vector of the pathogen in the transmission between domestic and wildlife animals. But the ticks are unimportant in the direct infection of humans. Cattles, sheep and goats are usually the source of transmission of this microorganism to humans. However cats, dogs and rabbits are also important in this regard. In most instances humans become infected with Coxiella burnetii following inhalation of contaminated aerosols (respiratory tract). The incubation period for Q-Fever in humans is about 2 weeks. The resulting illness can be divided into acute and chronic varieties. During the acute phase of illness antibodies to the phase 2-antigen are formed. Anti phase-1 antibodies in high titers are typical for a chronic disease.

In areas where Q-Fever is endemic, 12% or more of the population have antibodies to C. burnetii. Most of the infections are subclinical or undiagnosed. The acute infection shows symptoms of high fever, shivers, muscle pain and headache. Later on more severe diseases such as pneumonia or hepatitis can occur. Infections during pregnancy can lead to an abort or premature birth. Approximately 1% of all infections become chronic. The most frequent organ manifestation in Q-Fever is endocarditis.

Acute phase of Q-Fever
IgM specific to phase 2 after 2-3 weeks
IgG approximately 2 months after infection

Chronic phase of Q-Fever
From 6 weeks up to 4 months after infection phase 1 IgG and IgA antibodies can be detected.

2. INTENDED USE

The IBL America ELISA is intended for the determination of IgG class antibodies against Coxiella burnetii phase 1 in the early stages of infection in human serum. For research use only, not for use in diagnostic procedures.
3. PRINCIPLE OF THE ASSAY

The qualitative immunoenzymatic determination of IgG-class antibodies to Coxiella burnetii is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. Microwell strips are precoated with phase 1 antigens to bind corresponding antibodies of the sample. After washing the wells to remove all unbound sample material horseradish peroxidase (HRP) labelled anti-human IgG conjugate is added. This conjugate binds to the captured Coxiella burnetii-specific antibodies. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of phase 1-specific IgG antibodies in the sample. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450 nm is read using an ELISA microwell plate reader.

4. MATERIALS

4.1. Reagents supplied

- **C. burnetii phase 1 Coated Wells (IgG):** 12 breakapart 8-well snap-off strips coated with phase 1 antigens; in resealable aluminium foil.
- **IgG Sample Diluent***: 1 bottle containing 100 ml of buffer for sample dilution; pH 7.2 ± 0.2; coloured yellow; ready to use; white cap.
- **Stop Solution:** 1 bottle containing 15 ml acidic solution, 0.4 N; ready to use; red cap.
- **Washing Solution (20x conc.)***: 1 bottle containing 50 ml of a 20-fold concentrated buffer (pH 7.2 ± 0.2) for washing the wells; white cap.
- **C. burnetii anti-IgG Conjugate***: 1 bottle containing 20 ml of peroxidase labelled rabbit antibody to human IgG; coloured blue, ready to use; black cap.
- **TMB Substrate Solution:** 1 bottle containing 15 ml 3,3',5,5'-tetramethylbenzidine (TMB); ready to use; yellow cap.
- **C. burnetii IgG Positive Control***: 1 bottle containing 2 ml; coloured yellow; ready to use; red cap.
- **C. burnetii IgG Cut-off Control***: 1 bottle containing 3 ml; coloured yellow; ready to use; green cap.
- **C. burnetii IgG Negative Control***: 1 bottle containing 2 ml; coloured yellow; ready to use; blue cap.

* contains 0.1 % Bronidox L after dilution
** contains 0.2 % Bronidox L
*** contains 0.1 % Kathon

4.2. Materials supplied

- 1 Strip holder
- 1 Cover foil
- 1 Test protocol
- 1 distribution and identification plan
4.3. Materials and Equipment needed

- ELISA microwell plate reader, equipped for the measurement of absorbance at 450/620nm
- Incubator 37°C
- Manual or automatic equipment for rinsing wells
- Pipettes to deliver volumes between 10 and 1000 µl
- Vortex tube mixer
- Deionised or (freshly) distilled water
- Disposable tubes
- Pipe stand
- Timer

5. STABILITY AND STORAGE

The reagents are stable up to the expiry date stated on the label when stored at 2-8 °C.

6. REAGENT PREPARATION

It is very important to bring all reagents, samples and controls to room temperature (20-25°C) before starting the test run!

6.1. Coated snap-off strips

The ready to use breakapart snap-off strips are coated with phase 1 antigen. Store at 2...8°C. Immediately after removal of strips, the remaining strips should be resealed in the aluminium foil along with the desiccant supplied and stored at 2...8 °C; stability until expiry date. After first opening stability until expiry date when stored at 2...8°C.

6.2. C. burnetii anti-IgG Conjugate

The bottle contains 20ml of a solution with anti-human-IgG horseradish peroxidase, buffer, stabilizers, preservatives and an inert blue dye. The solution is ready to use. Store at 2-8°C. After first opening stability until expiry date when stored at 2-8°C.

6.3. Controls

The bottles labelled with Positive, Cut-off and Negative Control contain a ready to use control solution. It contains 0.1% Kathon and has to be stored at 2-8°C. After first opening stability until expiry date when stored at 2-8°C.

6.4. IgG Sample Diluent

The bottle contains 100ml phosphate buffer, stabilizers, preservatives and an inert yellow dye. It is used for the dilution of the sample. This ready to use solution has to be stored at 2-8°C. After first opening stability until expiry date when stored at 2-8°C.

6.5. Washing Solution (20xconc.)

The bottle contains 50 ml of a concentrated buffer, detergents and preservatives. Dilute Washing Solution 1+19; e.g. 10 ml Washing Solution + 190 ml fresh and germ free redistilled water. The diluted buffer is stable for 5 days at room temperature. After first opening stability until expiry date when stored at 2-8°C.
6.6. TMB Substrate Solution
The bottle contains 15 ml of a tetramethylbenzidine/hydrogen peroxide system. The reagent is ready to use and has to be stored at 2-8°C, away from the light. The solution should be colourless or could have a slight blue tinge. If the substrate turns into blue, it may have become contaminated and should be thrown away. After first opening stability until expiry date when stored at 2-8°C.

6.7. Stop Solution
The bottle contains 15 ml 0.4 N acidic solution (R 36/38, S 26). This ready to use solution has to be stored at 2-8°C. After first opening stability until expiry date.

7. SAMPLE COLLECTION AND PREPARATION
Use human serum samples with this assay. If the assay is performed within 5 days after sample collection, the samples should be kept at 2-8°C; otherwise they should be aliquotted and stored deep-frozen (-20 to -70°C). If samples are stored frozen, mix thawed samples well before testing. Avoid repeated freezing and thawing. Heat inactivation of samples is not recommended.

7.1. Sample Dilution
Before assaying, all samples should be diluted 1+100 with IgG Sample Diluent. Dispense 10µl sample and 1ml IgG Sample Diluent into tubes to obtain a 1+100 dilution and thoroughly mix with a Vortex.

8. ASSAY PROCEDURE
8.1. Test Preparation
Please read the test protocol carefully before performing the assay. Result reliability depends on strict adherence to the test protocol as described. If performing the test on ELISA automatic systems we recommend to increase the washing steps from three to five and the volume of washing solution from 300µl to 350µl to avoid washing effects. Prior to commencing the assay, the distribution and identification plan for all sample and controls should be carefully established on the result sheet supplied in the kit. Select the required number of microtiter strips or wells and insert them into the holder.

Please allocate at least:
1 well (e.g. A1) for the substrate blank,
1 well (e.g. B1) for the negative control,
2 wells (e.g. C1+D1) for the cut-off control and
1 well (e.g. E1) for the positive control.

It is recommended to determine controls and samples in duplicate, if necessary.

Perform all assay steps in the order given and without any appreciable delays between the steps.

A clean, disposable tip should be used for dispensing each control and sample. Adjust the incubator to 37° ± 1°C.
1. Dispense 100µl controls and diluted samples into their respective wells. Leave well A1 for substrate blank.
2. Cover wells with the foil supplied in the kit.
3. **Incubate for 1 hour ± 5 min at 37±1°C.**
4. When incubation has been completed, remove the foil, aspirate the content of the wells and wash each well three times with 300µl of Washing Solution. Avoid overflows from the reaction wells. The soak time between each wash cycle should be >5sec. At the end carefully remove remaining fluid by tapping strips on tissue paper prior to the next step!
   - Note: Washing is critical! Insufficient washing results in poor precision and falsely elevated absorbance values.
5. Dispense 100µl C. burnetii anti-IgG Conjugate into all wells except for the blank well (e.g. A1). Cover with foil.
6. **Incubate for 30 min at room temperature. Do not expose to direct sunlight.**
7. Repeat step 4.
8. Dispense 100µl TMB Substrate Solution into all wells
9. **Incubate for exactly 15 min at room temperature in the dark.**
10. Dispense 100µl Stop Solution into all wells in the same order and at the same rate as for the TMB Substrate Solution.
    - Any blue colour developed during the incubation turns into yellow.
    - Note: Highly positive samples can cause dark precipitates of the chromogen! These precipitates have an influence when reading the optical density. Predilution of the sample with physiological sodium chloride solution, for example 1+1, is recommended. Then dilute the sample 1+100 with dilution buffer and multiply the results in NTU by 2.
11. Measure the absorbance of the sample at 450/620nm within 30 min after addition of the Stop Solution.

### 8.2. Measurement

Adjust the ELISA Microwell Plate Reader to zero using the substrate blank in well A1.

*If - due to technical reasons - the ELISA reader cannot be adjusted to zero using the substrate blank in well A1, subtract the absorbance value of well A1 from all other absorbance values measured in order to obtain reliable results!*

**Measure the absorbance** of all wells at **450 nm** and record the absorbance values for each control and sample in the distribution and identification plan.

*Dual wavelength reading using 620 nm as reference wavelength is recommended.*

Where applicable calculate the **mean absorbance values** of all duplicates.
9. RESULTS

9.1. Run Validation Criteria
In order for an assay to be considered valid, the following criteria must be met:

- **Substrate blank** in A1: Absorbance value < 0.100.
- **Negative control** in B1: Absorbance value < 0.200 and < cut-off
- **Cut-off control** in C1 and D1: Absorbance value 0.150 – 1.30.
- **Positive control** in E1: Absorbance value > cut-off.

If these criteria are not met, the test is not valid and must be repeated.

9.2. Results
The cut-off is the mean absorbance value of the Cut-off control determinations.

*Example:* Absorbance value Cut-off control 0.39 + absorbance value Cut-off control 0.37 = 0.76 / 2 = 0.38

Cut-off = 0.38

10. SPECIFIC PERFORMANCE CHARACTERISTICS

10.1. Precision

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Mean (NTU)</th>
<th>Cv (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interassay</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>equivocal serum</td>
<td>5</td>
<td>9.62</td>
<td>2.4</td>
</tr>
<tr>
<td>Positive serum</td>
<td>6</td>
<td>27.4</td>
<td>3.5</td>
</tr>
<tr>
<td>Intraassay</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive serum</td>
<td>15</td>
<td>0.57</td>
<td>5.7</td>
</tr>
<tr>
<td>Positive serum</td>
<td>15</td>
<td>1.5</td>
<td>4.7</td>
</tr>
</tbody>
</table>

10.2. Specificity
The specificity is defined as the probability of the assay of scoring negative in the absence of the specific analyte. It is > 90 %.

10.3. Sensitivity
The sensitivity is defined as the probability of the assay of scoring positive in the presence of the specific analyte. It is 88 %.

10.4. Interferences
Interferences with hemolytic, lipemic or icteric sera are not observed up to a concentration of 10 mg/ml hemoglobin, 5 mg/ml triglycerides and 0.5 mg/ml bilirubin.

**Note:** The results refer to the groups of samples investigated; these are not guaranteed specifications.

11. LIMITATIONS OF THE PROCEDURE
Bacterial contamination or repeated freeze-thaw cycles of the sample may affect the absorbance values. Diagnosis of an infectious disease should not be established on the basis of a single test result. A precise diagnosis should take into consideration history, symptomatology as well as serological data.

In immunocompromised patients and newborns serological data only have restricted value.
12. PRECAUTIONS AND WARNINGS

- In compliance with article 1 paragraph 2b European directive 98/79/EC the use of the medical devices is intended by the manufacturer to secure suitability, performances and safety of the product. Therefore the test procedure, the information, the precautions and warnings in the instructions for use have to be strictly followed. The use of the testkits with analyzers and similar equipment has to be validated. Any change in design, composition and test procedure as well as for any use in combination with other products not approved by the manufacturer is not authorized; the user himself is responsible for such changes. The manufacturer is not liable for false results and incidents for these reasons. The manufacturer is not liable for any results by visual analysis of the samples.
- For research use only.
- All components of human origin used for the production of these reagents have been tested for anti-HIV antibodies, anti-HCV antibodies and HBsAg and have been found to be non-reactive. Nevertheless, all materials should still be regarded and handled as potentially infectious.
- Do not interchange reagents or strips of different production lots.
- No reagents of other manufacturers should be used along with reagents of this test kit.
- Do not use reagents after expiry date stated on the label.
- Use only clean pipette tips, dispensers, and lab ware.
- Do not interchange screw caps of reagent vials to avoid cross-contamination.
- Close reagent vials tightly immediately after use to avoid evaporation and microbial contamination.
- After first opening and subsequent storage check conjugate and control vials for microbial contamination prior to further use.
- To avoid cross-contamination and falsely elevated results pipette samples and dispense conjugate without splashing accurately to the bottom of wells.
- The ELISA is only designed for qualified personnel who are familiar with good laboratory practice.

| WARNING:    | In the used concentration Bronidox L has hardly any toxicological risk upon contact with skin and mucous membranes! |
| WARNING:    | Acidic solution irritates eyes and skin. Keep out of the reach of children. Upon contact with the eyes, rinse thoroughly with water and consult a doctor! |

12.1. Disposal Considerations
Residues of chemicals and preparations are generally considered as hazardous waste. The disposal of this kind of waste is regulated through national and regional laws and regulations. Contact your local authorities or waste management companies which will give advice on how to dispose hazardous waste.

Manufactured for:
Immuno-Biological Laboratories, Inc. (IBL-America)
8201 Central Ave. NE, Suite P, Minneapolis, Minnesota 55432, USA
Phone: +1 (763) - 780-2955 Fax.: +1 (763) - 780-2988
Email: ibl@ibl-america.com Web: www.ibl-america.com
## Symbols used with IBL AMERICA ELISAs

<table>
<thead>
<tr>
<th>Symbol</th>
<th>English</th>
<th>Deutsch</th>
<th>Français</th>
<th>Españ/ol</th>
<th>Italiano</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="European Conformity" /></td>
<td>European Conformity</td>
<td>CE-Konformitäts-kennzeichnung</td>
<td>Conforme aux normes européennes</td>
<td>Conformidad europea</td>
<td>Conformità europea</td>
</tr>
<tr>
<td><img src="image" alt="Consult instructions for use" /></td>
<td>Consult instructions for use</td>
<td>Gebrauchsanweisung beachten</td>
<td>Consulter les instructions d’utilisation</td>
<td>Consulte las Instrucciones</td>
<td>Consultare le istruzioni per l’uso</td>
</tr>
<tr>
<td><img src="image" alt="In vitro diagnostic device" /></td>
<td>In vitro diagnostic device</td>
<td>In-vitro-Diagnostikum</td>
<td>Usage Diagnostic in vitro</td>
<td>Para uso Diagnostico in vitro</td>
<td>Per uso Diagnostica in vitro</td>
</tr>
<tr>
<td><img src="image" alt="For research use only" /></td>
<td>For research use only</td>
<td>Nur für Forschungszwecke</td>
<td>Seulement dans le cadre de recherches</td>
<td>Sólo para uso en investigación</td>
<td>Solo a scopo di ricerca</td>
</tr>
<tr>
<td><img src="image" alt="Catalogue number" /></td>
<td>Catalogue number</td>
<td>Katalog-Nr.</td>
<td>Référence</td>
<td>Número de catálogo</td>
<td>No. di Cat.</td>
</tr>
<tr>
<td><img src="image" alt="Lot. No. / Batch code" /></td>
<td>Lot. No. / Batch code</td>
<td>Chargen-Nr.</td>
<td>No. de lot</td>
<td>Número de lote</td>
<td>Lotto no</td>
</tr>
<tr>
<td><img src="image" alt="Contains sufficient for &lt;n&gt; tests/" /></td>
<td>Contains sufficient for &lt;n&gt; tests/</td>
<td>Ausreichend für “n” Ansätze</td>
<td>Contenu suffisant pour “n” tests</td>
<td>Contenido suficiente para “n” ensayos</td>
<td>Contenuto sufficiente per “n” saggi</td>
</tr>
<tr>
<td><img src="image" alt="Storage Temperature" /></td>
<td>Storage Temperature</td>
<td>Lagerungstemperatur</td>
<td>Température de conservation</td>
<td>Temperatura de conservación</td>
<td>Temperatura di conservazione</td>
</tr>
<tr>
<td><img src="image" alt="Expiration Date" /></td>
<td>Expiration Date</td>
<td>Mindesthaltbarkeits-datum</td>
<td>Date limite d’utilisation</td>
<td>Fecha de caducidad</td>
<td>Data di scadenza</td>
</tr>
<tr>
<td><img src="image" alt="Legal Manufacturer" /></td>
<td>Legal Manufacturer</td>
<td>Hersteller</td>
<td>Fabricant</td>
<td>Fabricante</td>
<td>Fabbricante</td>
</tr>
<tr>
<td><img src="image" alt="Distributed by" /></td>
<td>Distributed by</td>
<td>Distributor</td>
<td>Vertrieber</td>
<td>Distributeur</td>
<td>Distributore</td>
</tr>
<tr>
<td><img src="image" alt="Content" /></td>
<td>Content</td>
<td>Content</td>
<td>Inhalt</td>
<td>Contenu</td>
<td>Contenido</td>
</tr>
<tr>
<td><img src="image" alt="Volume/No." /></td>
<td>Volume/No.</td>
<td>Volumen/Anzahl</td>
<td>Volume/Numéro</td>
<td>Volumen/Número</td>
<td>Volume/Quantità</td>
</tr>
<tr>
<td><img src="image" alt="Microtiterwells" /></td>
<td>Microtiterwells</td>
<td>Mikrotiterwells</td>
<td>Plaques de micro-titration</td>
<td>Placas multipocillo</td>
<td>Micropozzetti</td>
</tr>
<tr>
<td><img src="image" alt="Antiserum" /></td>
<td>Antiserum</td>
<td>Antisérum</td>
<td>Antiserum</td>
<td>Antisuero</td>
<td>Antisiero</td>
</tr>
<tr>
<td><img src="image" alt="Enzyme Conjugate" /></td>
<td>Enzyme Conjugate</td>
<td>Enzymkonjugat</td>
<td>Conjugé enzymatique</td>
<td>Conjugado enzimático</td>
<td>Tracciante enzimatico</td>
</tr>
<tr>
<td><img src="image" alt="Enzyme Complex" /></td>
<td>Enzyme Complex</td>
<td>Enzymkomplex</td>
<td>Complexe enzymatique</td>
<td>Complex enzimático</td>
<td>Compleso enzimatico</td>
</tr>
<tr>
<td><img src="image" alt="Substrate Solution" /></td>
<td>Substrate Solution</td>
<td>Substratlösung</td>
<td>Solution substrat</td>
<td>Solución de sustrato</td>
<td>Soluzione di substrato</td>
</tr>
<tr>
<td><img src="image" alt="Stop Solution" /></td>
<td>Stop Solution</td>
<td>Stoplösung</td>
<td>Solution d’arrêt</td>
<td>Solución de parada</td>
<td>Soluzione d’ arresto</td>
</tr>
<tr>
<td><img src="image" alt="Zero Standard" /></td>
<td>Zero Standard</td>
<td>Nullstandard</td>
<td>Zero Standard</td>
<td>Estándar cero</td>
<td>Standard zero</td>
</tr>
<tr>
<td><img src="image" alt="Standard" /></td>
<td>Standard</td>
<td>Standard</td>
<td>Standard</td>
<td>Estándar</td>
<td>Standard</td>
</tr>
<tr>
<td><img src="image" alt="Control" /></td>
<td>Control</td>
<td>Kontrolle</td>
<td>Contrôle</td>
<td>Control</td>
<td>Controllo</td>
</tr>
<tr>
<td><img src="image" alt="Assay Buffer" /></td>
<td>Assay Buffer</td>
<td>Assaypuffer</td>
<td>Tampon d’essai</td>
<td>Tampón de ensayo</td>
<td>Tampone del test</td>
</tr>
<tr>
<td><img src="image" alt="Wash Solution" /></td>
<td>Wash Solution</td>
<td>Waschlösung</td>
<td>Solution de lavage</td>
<td>Solución de lavado</td>
<td>Soluzione di lavaggio</td>
</tr>
<tr>
<td><img src="image" alt="1N NaOH" /></td>
<td>1N NaOH</td>
<td>1N NaOH</td>
<td>1N NaOH</td>
<td>1N NaOH</td>
<td>1N NaOH (idrossido di sodio 1N)</td>
</tr>
<tr>
<td><img src="image" alt="1 N HCl" /></td>
<td>1 N HCl</td>
<td>1 N HCl</td>
<td>1N HCl</td>
<td>1 N HCl</td>
<td>1 N HCl</td>
</tr>
<tr>
<td><img src="image" alt="Sample Diluent" /></td>
<td>Sample Diluent</td>
<td>Probenverdünnungsmedium</td>
<td>Solution pour dilution de l’échantillon</td>
<td>Solución para dilución de la muestra</td>
<td>Diluente dei campioni</td>
</tr>
<tr>
<td><img src="image" alt="Conjugate Diluent" /></td>
<td>Conjugate Diluent</td>
<td>Konjugatverdünnungsmedium</td>
<td>Solution pour dilution du conjugué</td>
<td>Solución para dilución del conjugado</td>
<td>Diluente del tracciante</td>
</tr>
</tbody>
</table>
# SCHEME OF THE ASSAY

Coxiella burnetii (Q-Fever) Phase 1 IgG-ELISA

## Test preparation

Prepare reagents and samples as described. Establish the distribution and identification plan for all samples and controls on the result sheet supplied in the kit. Select the required number of microtiter strips or wells and insert them into the holder.

## Assay procedure

<table>
<thead>
<tr>
<th>Substrate blank (e.g. A1)</th>
<th>Negative control</th>
<th>Positive control</th>
<th>Cut-off control</th>
<th>Sample (diluted 1+100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control</td>
<td>100µl</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Positive control</td>
<td>-</td>
<td>100µl</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cut-off control</td>
<td>-</td>
<td>-</td>
<td>100µl</td>
<td>-</td>
</tr>
<tr>
<td>Sample (diluted 1+100)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100µl</td>
</tr>
</tbody>
</table>

Cover wells with foil supplied in the kit

**Incubate for 1 h at 37°C**

Wash each well three times with 300µl of washing solution

<table>
<thead>
<tr>
<th>Conjugate</th>
<th>100µl</th>
<th>100µl</th>
<th>100µl</th>
<th>100µl</th>
</tr>
</thead>
</table>

Cover wells with foil supplied in the kit

**Incubate for 30 min at room temperature**

Wash each well three times with 300µl of washing solution

<table>
<thead>
<tr>
<th>TMB Substrate</th>
<th>100µl</th>
<th>100µl</th>
<th>100µl</th>
<th>100µl</th>
<th>100µl</th>
</tr>
</thead>
</table>

**Incubate for exactly 15 min at room temperature in the dark**

<table>
<thead>
<tr>
<th>Stop Solution</th>
<th>100µl</th>
<th>100µl</th>
<th>100µl</th>
<th>100µl</th>
<th>100µl</th>
</tr>
</thead>
</table>

Photometric measurement at 450 nm (reference wavelength: 620 nm)